🎉 M&A multiples are live!
Check it out!

CureVac Valuation Multiples

Discover revenue and EBITDA valuation multiples for CureVac and other public comps.

See CureVac Valuation Multiples

CureVac Overview

About CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.


Founded

2020

HQ

United States of America
Employees

1.1K+

Website

curevac.com

Financials

LTM Revenue $507M

LTM EBITDA $203M

EV

$269M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CureVac Financials

CureVac has a last 12-month revenue of $507M and a last 12-month EBITDA of $203M.

In the most recent fiscal year, CureVac achieved revenue of $53.8M and an EBITDA of -$234M.

CureVac expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CureVac valuation multiples based on analyst estimates

CureVac P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $67.4M $53.8M $536M $507M XXX
Gross Profit -$135M -$117M -$70.6M XXX XXX
Gross Margin -201% -217% -13% XXX XXX
EBITDA -$222M -$234M $231M $203M XXX
EBITDA Margin -329% -435% 43% 40% XXX
Net Profit -$412M -$249M -$260M XXX XXX
Net Margin -611% -463% -49% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

CureVac Stock Performance

As of February 7, 2025, CureVac's stock price is $4.

CureVac has current market cap of $803M, and EV of $269M.

See CureVac trading valuation data

CureVac Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$269M $803M XXX XXX XXX XXX $0.68

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CureVac Valuation Multiples

As of February 7, 2025, CureVac has market cap of $803M and EV of $269M.

CureVac's trades at 0.6x LTM EV/Revenue multiple, and 1.4x LTM EBITDA.

Analysts estimate CureVac's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CureVac and 10K+ public comps

CureVac Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $269M XXX XXX XXX
EV/Revenue 0.5x XXX XXX XXX
EV/EBITDA 1.2x XXX XXX XXX
P/E 4.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CureVac Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CureVac Valuation Multiples

CureVac's NTM/LTM revenue growth is -85%

CureVac's revenue per employee for the last fiscal year averaged $48K, while opex per employee averaged $0.2M for the same period.

Over next 12 months, CureVac's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CureVac's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CureVac and other 10K+ public comps

CureVac Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 897% XXX XXX XXX XXX
EBITDA Margin 43% XXX XXX XXX XXX
EBITDA Growth -199% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -42% XXX XXX XXX XXX
Revenue per Employee $48K XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 1% XXX XXX XXX XXX
G&A Expenses to Revenue 141% XXX XXX XXX XXX
R&D Expenses to Revenue 215% XXX XXX XXX XXX
Opex to Revenue 383% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

CureVac Public Comps

See valuation multiples for CureVac public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CureVac M&A and Investment Activity

CureVac acquired  XXX companies to date.

Last acquisition by CureVac was  XXXXXXXX, XXXXX XXXXX XXXXXX . CureVac acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CureVac

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CureVac

When was CureVac founded? CureVac was founded in 2020.
Where is CureVac headquartered? CureVac is headquartered in United States of America.
How many employees does CureVac have? As of today, CureVac has 1.1K+ employees.
Who is the CEO of CureVac? CureVac's CEO is Dr. Alexander Zehnder, M.B.A.,M.D..
Is CureVac publicy listed? Yes, CureVac is a public company listed on NAS.
What is the stock symbol of CureVac? CureVac trades under CVAC ticker.
When did CureVac go public? CureVac went public in 2020.
Who are competitors of CureVac? Similar companies to CureVac include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of CureVac? CureVac's current market cap is $803M
What is the current revenue of CureVac? CureVac's last 12-month revenue is $507M.
What is the current EBITDA of CureVac? CureVac's last 12-month EBITDA is $203M.
What is the current EV/Revenue multiple of CureVac? Current revenue multiple of CureVac is 0.6x.
What is the current EV/EBITDA multiple of CureVac? Current EBITDA multiple of CureVac is 1.4x.
What is the current revenue growth of CureVac? CureVac revenue growth between 2023 and 2024 was 897%.
Is CureVac profitable? Yes, CureVac is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.